Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholera - Overview
Cholera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cholera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholera - Companies Involved in Therapeutics Development
Emergent BioSolutions Inc
Global BioLife Inc Ltd
po Pharmaceuticals Inc
Ostrich Pharma USA Inc
Vanda Pharmaceuticals Inc
Cholera - Drug Profiles
Antibodies for Cholera - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPO-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera (whole cell) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera strain [CVD 103-HgR] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholera vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholvax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gram-negative bacterial infections vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMSUTMR-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholera - Dormant Projects
Cholera - Discontinued Products
Cholera - Product Development Milestones
Featured News & Press Releases
Jan 28, 2021: CHMP recommended extensions of indication for Vaxchora
Jan 31, 2020: Emergent BioSolutions receives positive CHMP opinion for Vaxchora; anticipates near-term approval by European Medicines Agency
Jun 04, 2019: Emergent BioSolutions announces FDA approval of change in storage conditions and transfer of manufacturing for its cholera vaccine
Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks
Dec 11, 2017: PaxVax: Single-dose vaccine could provide faster protection in cholera epidemics
Dec 06, 2017: Randomized Placebo-Controlled Study Provides Encouraging Results for a Higher Dose Formulation of Vaxchora (CVD 103-HgR) as a Potential Tool in Containing Cholera Epidemics
Oct 24, 2016: PaxVax’s Vaxchora Now Available as the Only U.S. Approved Vaccine for Protection Against Cholera
Jun 23, 2016: CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine
Jun 20, 2016: FDA Approves PaxVax to Manufacture Vaxchora (Oral Cholera Vaccine) at SynCo Bio Partners
Jun 10, 2016: FDA approves vaccine to prevent cholera for travelers
Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine
Dec 16, 2015: U.S. Food and Drug Administration Accepts Biologics License Application for PaxVax’s Single-Dose Oral Cholera Vaccine Vaxchora
Feb 03, 2015: po Files Brief on Appeal In Dispute With Salix
Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial
Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Cholera, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Cholera, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Cholera - Pipeline by Emergent BioSolutions Inc, 2021
Cholera - Pipeline by Global BioLife Inc Ltd, 2021
Cholera - Pipeline by Napo Pharmaceuticals Inc, 2021
Cholera - Pipeline by Ostrich Pharma USA Inc, 2021
Cholera - Pipeline by Vanda Pharmaceuticals Inc, 2021
Cholera - Dormant Projects, 2021
Cholera - Discontinued Products, 2021